References of "Revue Médicale Suisse"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailUtilisation des antidiabetiques oraux en cas d'insuffisance renale.
SCHEEN, André ULiege

in Revue Médicale Suisse (2012), 8(351), 1614-20

People with chronic kidney disease (CKD) of stages 3-4 (creatinine clearance <50 ml/min) represent 25-30% of type 2 diabetic patients, but the problem is often underrecognized or neglected in clinical ... [more ▼]

People with chronic kidney disease (CKD) of stages 3-4 (creatinine clearance <50 ml/min) represent 25-30% of type 2 diabetic patients, but the problem is often underrecognized or neglected in clinical practice. However, most of oral antidiabetic agents have limitations in case of renal impairment, either because they require a dose adjustment, or because they are contra-indicated for safety reasons. It is the case for metformin (risk of lactic acidosis) and for most sulfonylureas (risk of hypoglycaemia). New antidiabetic agents are better tolerated in case of CKD. However, the daily dose of dipeptidyl peptidase-4 inhibitors should be adjusted (except for linagliptin). Concerning new inhibitors of renal SGLT2 cotransporters, they have a reduced efficacy and their safety remains to be demonstrated in presence of CKD. [less ▲]

Detailed reference viewed: 135 (2 ULiège)
Full Text
Peer Reviewed
See detailInhibiteurs du cotransporteur du glucose SGLT rénal pour traiter le diabète de type 2
SCHEEN, André ULiege; RADERMECKER, Régis ULiege; ERNEST, Philippe ULiege et al

in Revue Médicale Suisse (2011), 7(306), 1621-1629

Detailed reference viewed: 45 (12 ULiège)
Full Text
Peer Reviewed
See detailHypophosphatémie et ostéomalacie oncogénique
Van der Rest, Catherine; CAVALIER, Etienne ULiege; COLSON, Laurent ULiege et al

in Revue Médicale Suisse (2011), 7

In this article, we will discuss about hypophosphatemia due to tumor-induced osteomalacia. This disease is characterized by severe muscular and articular tenderness inducing profound walking limitation ... [more ▼]

In this article, we will discuss about hypophosphatemia due to tumor-induced osteomalacia. This disease is characterized by severe muscular and articular tenderness inducing profound walking limitation. Clinical chemistry results show severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth factor 23 (FGG-23) is abnormally high. Physiological role of FGF-23 is examined. We also consider the pathophysiology of tumor induced osteomalacia, the use of different investigations to localize the tumor and therapies available to treat this rare disease. [less ▲]

Detailed reference viewed: 144 (9 ULiège)
Full Text
Peer Reviewed
See detailLymphome du manteau : prise en charge 2011
Bonnet, Christophe ULiege; CAERS, Jo ULiege; DE PRIJCK, Bernard ULiege et al

in Revue Médicale Suisse (2011), 7

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14 ... [more ▼]

Le lymphome du manteau (LM) représente 6% des lymphomes non hodgkiniens (LNH). Le diagnostic repose sur l'immunophénotypage et la démonstration de la présence de la location entre les chromosomes 11 et 14, avec surexpression de la cycline D1. Le traitement de première ligne du sujet jeune associe trois cures de R-CHOP21 alternées avec trois cures de R-DHAP21, suivies d'une autogreffe conditionnée par irradiation corporelle totale, cyclophosphamide et aracytine. Le sujet de plus de 65 ans peut bénéficier de huit cures de R-CHOP21. L'intérêt du traitement de maintenance est en cours d'évaluation. L'allogreffe de cellules souches hématopoïétiques offre une chance de guérison aux patients en rechute en bon état général. Les traitements ciblés permettront une amélioration du pronostic de cette maladie. [less ▲]

Detailed reference viewed: 117 (5 ULiège)
Full Text
Peer Reviewed
See detailDiabete de type 2 et medicaments anti-inflammatoires: nouvelles perspectives therapeutiques?
Esser, Nathalie ULiege; Paquot, Nicolas ULiege; SCHEEN, André ULiege

in Revue Médicale Suisse (2011), 7(306), 1614-81620

It is now well accepted that a chronic, low-grade inflammation is observed in abdominal obesity, insulin resistance and type 2 diabetes mellitus, and that pro-inflammatory cytokines and oxidative stress ... [more ▼]

It is now well accepted that a chronic, low-grade inflammation is observed in abdominal obesity, insulin resistance and type 2 diabetes mellitus, and that pro-inflammatory cytokines and oxidative stress play a role in the pathogenesis of type 2 diabetes. These new findings raise the question of whether antiinflammatory strategies may have a place in the prevention and treatment of type 2 diabetes. This review article describes the results obtained in studies on patients with metabolic syndrome or type 2 diabetes aiming to test the metabolic effect of anti-inflammatory (salicylates, antagonists of interleukine-1, antagonists of tumor necrosis factor-alpha) and anti-oxydants (succinobucol) drugs. [less ▲]

Detailed reference viewed: 219 (6 ULiège)
Full Text
Peer Reviewed
See detail"The lower, the better": pas d'accord sur le rapport benefices/risques apres "ACCORD".
SCHEEN, André ULiege

in Revue Médicale Suisse (2011), 7(306), 1603-4

Detailed reference viewed: 30 (2 ULiège)
Full Text
Peer Reviewed
See detailPrise en charge actuelle des syndromes myélodysplasiques
CAERS, Jo ULiege; BONNET, Christophe ULiege; GRAUX, Carlos et al

in Revue Médicale Suisse (2011), 7

Detailed reference viewed: 39 (9 ULiège)
Full Text
Peer Reviewed
See detailQuelle cible tensionnelle idéale pour nos patients hypertendus en 2010?
Krzesinski, Jean-Marie ULiege; Saint-Remy, Annie ULiege

in Revue Médicale Suisse (2010), 6

Les directives du traitement de l'hypertension artérielle de 2007 ont été rediscutées en 2009. Quelle que soit la pathologie associée à l'hypertension artérielle, la cible à atteindre est : 130 à 139 mmHg ... [more ▼]

Les directives du traitement de l'hypertension artérielle de 2007 ont été rediscutées en 2009. Quelle que soit la pathologie associée à l'hypertension artérielle, la cible à atteindre est : 130 à 139 mmHg pour la systolique et 80 à 85 mmHg pour la diastolique. Si le patient peut tolérer une pression plus basse, on ne freinera pas l’abaissement de pression. Beaucoup de questions restent cependant encore sans réelles réponses quant à des cibles plus basses en fonction de l’âge et de situations pathologiques individuelles. Le choix des agents antihypertenseurs devient primordial lors d’un risque cardiovasculaire majeur. Il convient toujours d’appliquer des règles hygiéno-diététiques à l’ensemble de la population hypertendue et d’agir sur tous les facteurs de risque associés. [less ▲]

Detailed reference viewed: 66 (4 ULiège)
Full Text
Peer Reviewed
See detailActualités thérapeutiques dans la cardiomyopathie hypertrophique.
Moonen, Marie ULiege; Pierard, Luc ULiege

in Revue Médicale Suisse (2010), 6(260), 1591-4

The management of patients with hypertrophic cardiomyopathy has largely evolved over the past two decades. One important finding is that medical treatment appears under used. Invasive procedure are ... [more ▼]

The management of patients with hypertrophic cardiomyopathy has largely evolved over the past two decades. One important finding is that medical treatment appears under used. Invasive procedure are reserved to patients with obstructive hypertrophic cardiomyopathy who remain symptomatic despite optimal medical treatment. Indications for implantable cardiac defibrillator are still debated. A global and multidisciplinary approach of the patient and of his family is mandatory. [less ▲]

Detailed reference viewed: 55 (7 ULiège)
Full Text
Peer Reviewed
See detailApproche multirisque du patient diabetique de type 2: desaccord sur les valeurs cibles suite a l'etude ACCORD.
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale Suisse (2010), 6(260), 1582-7

The ACCORD trial investigated the effects of intensifying the global management of 10,251 type 2 diabetic patients, with established cardiovascular disease or at least two other cardiovascular risk ... [more ▼]

The ACCORD trial investigated the effects of intensifying the global management of 10,251 type 2 diabetic patients, with established cardiovascular disease or at least two other cardiovascular risk factors, on a composite endpoint (non fatal myocardial infarction, stroke and cardiovascular death). The attempt to reduce HbA1c level below 6% was associated with an increased cardiovascular mortality (despite a reduction in non fatal myocardial infarcts); lowering systolic blood pressure below 120 mmHg instead of 140 mmHg did not provide any additional benefit; finally, the control of atherogenic dyslipidaemia, with fenofibrate added to a statin, did not modify the composite endpoint (despite a positive effect in the subgroup of patients with high triglycerides and low HDL cholesterol). These rather disappointing results should be interpreted to provide practical guidelines. [less ▲]

Detailed reference viewed: 114 (3 ULiège)
Full Text
Peer Reviewed
See detailReduction du risque metabolique associe a l'obesite en modulant l'exposition tissulaire au cortisol.
Iovino, Alessandra ULiege; Paquot, Nicolas ULiege; Scheen, André ULiege

in Revue Médicale Suisse (2010), 6(260), 1608-12

The 11-beta-hydroxysteroid dehydrogenase type 1 (11HSD1) enzyme promotes the local conversion from cortisone to cortisol, especially in the liver and the adipose tissue. It may play a role in the ... [more ▼]

The 11-beta-hydroxysteroid dehydrogenase type 1 (11HSD1) enzyme promotes the local conversion from cortisone to cortisol, especially in the liver and the adipose tissue. It may play a role in the pathophysiology of abdominal obesity and the metabolic syndrome, both showing some similarities with the Cushing syndrome. Considering experimental results obtained in rodents, the inhibition of this enzyme could exert favourable metabolic effects, with significant reductions in plasma glucose, insulin resistance and dyslipidaemia. Synthetic inhibitors of 11HSD1 are currently in development with encouraging preliminary results, first in animals, and more recently in humans. Selective inhibitors of 11HSD1 may represent an innovative approach in the pharmacological management of obesity, metabolic syndrome and type 2 diabetes in a near future. [less ▲]

Detailed reference viewed: 116 (10 ULiège)
Full Text
Peer Reviewed
See detailActivite anticancereuse de la metformine: nouvelles perspectives pour une vieille molecule.
Beck, Emmanuel ULiege; Scheen, André ULiege

in Revue Médicale Suisse (2010), 6(260), 1601-7

Le diabète de type 2 est associé à un risque accru de cancer, d’autant plus évident qu’on maîtrise mieux la mortalité cardio-vasculaire. Tous les traitements antidiabétiques n’ont pas le même impact sur ... [more ▼]

Le diabète de type 2 est associé à un risque accru de cancer, d’autant plus évident qu’on maîtrise mieux la mortalité cardio-vasculaire. Tous les traitements antidiabétiques n’ont pas le même impact sur le cancer : le risque est accru avec les sulfonylurées et diminué avec la metformine (et les glitazones). De nombreuses études épidémiologiques observationnelles et cas-témoins récentes révèlent qu’un traitement par metformine est associé à une nette réduction de l’incidence de néoplasies et de la mortalité par cancer. Il existe une relation doseréponse et une relation entre la durée préalable du traitement par metformine et l’effet protecteur observé. Les mécanismes invoqués sont l’activation de l’enzyme AMPK et l’inhibition de la voie mTOR. Des études avec la metformine sont en cours en oncologie, notamment dans le cancer du sein. [less ▲]

Detailed reference viewed: 154 (2 ULiège)
Full Text
Peer Reviewed
See detailA propos de l'inertie et de la non-observance therapeutiques.
Scheen, André ULiege

in Revue Médicale Suisse (2010), 6(260), 1571-2

Detailed reference viewed: 71 (8 ULiège)
Full Text
Peer Reviewed
See detailEducation therapeutique et mesure continue de la glycemie chez le patient diabetique insulino-traite.
Thielen, Vinciane ULiege; Radermecker, Régis ULiege; Renard, Eric et al

in Revue Médicale Suisse (2010), 6(260), 1596-600

L’efficacité d’un programme éducationnel fondé sur l’utilisation d’une mesure continue du glucose avec un affichage en temps réel a été évaluée chez des patients diabétiques de type 1 (système couplé à ... [more ▼]

L’efficacité d’un programme éducationnel fondé sur l’utilisation d’une mesure continue du glucose avec un affichage en temps réel a été évaluée chez des patients diabétiques de type 1 (système couplé à une pompe à insuline externe - Paradigm Real Time®) et chez des patients diabétiques de type 2 mal contrôlés sous insuline (système Guardian RT® une semaine par mois pendant 3 mois versus automesure classique). Ces deux essais pilote montrent une diminution du taux d’hémoglobine glyquée (HbA1c) avec le « glucose sensor », avec moins d’hypoglycémies symptomatiques. Malgré certaines difficultés techniques (surtout chez les diabétiques de type 2), l’approche représente un outil intéressant d’éducation thérapeutique. Ces résultats prometteurs plaident pour des études de plus grande envergure chez des patients diabétiques bien sélectionnés. [less ▲]

Detailed reference viewed: 167 (11 ULiège)
Full Text
Peer Reviewed
See detailTraitement de la maladie de Parkinson en 2009.
MAERTENS DE NOORDHOUT, Alain ULiege

in Revue Médicale Suisse (2009), 5(214), 1650-5

The cause of Parkinson's disease remains unknown and no cure or prevention exists so far. Levodopa remains by far the most potent symptomatic therapy, but induces side-effects such as motor fluctuations ... [more ▼]

The cause of Parkinson's disease remains unknown and no cure or prevention exists so far. Levodopa remains by far the most potent symptomatic therapy, but induces side-effects such as motor fluctuations and abnormal movements, which can somewhat be counterbalanced by optimizing levodopa plasma levels or acting at receptors level with long half-life dopamine agonists. In severe cases, functional surgery with deep brain stimulation can be offered. Some non-dopaminergic symptoms like dementia, freezing, postural instability or dysautonomia do not respond to dopaminergic drugs and need special care. [less ▲]

Detailed reference viewed: 67 (25 ULiège)
Full Text
Peer Reviewed
See detailQuel avenir pour les essais de prevention cardiovasculaire?
Scheen, André ULiege

in Revue Médicale Suisse (2009), 5(214), 1635-6

Detailed reference viewed: 32 (1 ULiège)
Full Text
Peer Reviewed
See detailTraitements actuels du lymphome folliculaire
Bonnet, Christophe ULiege; Beguin, Yves ULiege; De Prijck, Bernard ULiege et al

in Revue Médicale Suisse (2009), 5

After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the ... [more ▼]

After diffuse large B-cell lymphoma, follicular lymphoma is the most frequent non-Hodgkin's lymphoma. It remains incurable, except for localized diseases. Advanced disease has to be treated only in the presence of clinical and/or biology aggressiveness. These patients should be treated by rituximab (Mab-Thera) associated to polychemotherapy comprising cyclophosphamide, vincristine and prednisone. After this therapy, the benefit of rituximab in maintenance has to be confirmed. Autologous stem cell transplantation is also an interesting option. The other therapeutic options comprise radio-immunotherapy with 90Y ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade). [less ▲]

Detailed reference viewed: 492 (5 ULiège)
Full Text
Peer Reviewed
See detailTrouble obsessionnel-compulsif (TOC).
Debabeche, Cécile ULiege; Muselle, Alice ULiege; Servais, Sophie ULiege et al

in Revue Médicale Suisse (2009), 5(214), 1659-62

Obsessive compulsive disorder (OCD) is a frequent and disabling psychic illness. Along psychiatric history, several etiological models have been successively hypothesized to explain the obsessive ... [more ▼]

Obsessive compulsive disorder (OCD) is a frequent and disabling psychic illness. Along psychiatric history, several etiological models have been successively hypothesized to explain the obsessive compulsive symptoms from a psychological, behavioural or biological point of view. This review aims at presenting OCD etiological models as well as describing OCD clinical and therapeutic aspects. [less ▲]

Detailed reference viewed: 251 (29 ULiège)
Full Text
Peer Reviewed
See detailSyndromes paranéoplasiques endocriniens: diagnostic et prise en charge.
Valdes Socin, Hernan Gonzalo ULiege; Niaourou, V.; Vandeva, S. et al

in Revue Médicale Suisse (2009), 5(214), 1668-74

Paraneoplastic endocrine syndromes define a group of secondary signs and symptoms associated to a neoplasia, independently from the location of the primary tumor or its metastases. Paraneoplastic or ... [more ▼]

Paraneoplastic endocrine syndromes define a group of secondary signs and symptoms associated to a neoplasia, independently from the location of the primary tumor or its metastases. Paraneoplastic or ectopic endocrine syndromes usually result from aberrant hormone precursors or hormone-like substances by tumours. Knowledge of paraneoplastic endocrine complications is important both for the early diagnosis of neoplasia and the prognosis of the patient. In this review we discuss almost all reported paraneoplastic endocrine syndromes. We analyze their prevalence, etiology, laboratory diagnosis and treatment. [less ▲]

Detailed reference viewed: 70 (2 ULiège)
Full Text
Peer Reviewed
See detailIndications cliniques de la radiotherapie metabolique dans les lymphomes
Witvrouw, Nancy ULiege; De Prijck, Bernard ULiege; Hustinx, Roland ULiege

in Revue Médicale Suisse (2008), 4(168), 1818-22

In their later stages low grade lymphoma are incurable. These lymphomas being radio-sensitive, a treatment of metabolic radioimmunotherapy, using monoclonal antibodies (anti-CD20) as the carrier has been ... [more ▼]

In their later stages low grade lymphoma are incurable. These lymphomas being radio-sensitive, a treatment of metabolic radioimmunotherapy, using monoclonal antibodies (anti-CD20) as the carrier has been developed. The aim of this treatment is to use these antibodies to target radiation to tumor tissues while limiting toxicity to normal cells. Ibritumomab tiuxetan (Zevalin) is currently prescribed for patients with relapsed or refractory low-grade follicular lymphoma after rituximab treatment. This outpatient treatment has a high level of overall response rate including complete response and that for a long period. The side effects are essentially hematological and reversible. In the near future many more indications should become apparent and Zevalin should become an important tool in the B-cell lymphoma (low and high grade). [less ▲]

Detailed reference viewed: 93 (4 ULiège)